Verpasse nicht deinen Gratis-Zugang zum aktien-Magazin!

finanzen.net ZERO schenkt dir das TraderFox aktien-Magazin (Wert: 147 €)

Sichere dir 50 € Bonus on top – starte einfach mit dem Promocode 'SOMMER2026'

Überzeuge dich selbst vom mehrfachen Kostensieger der Stiftung Warentest (12/2025)

Viatris Aktie

15,14 EUR -0,18 EUR -1,20 %

14:53:00

STU

17,63 USD +0,06 USD +0,31 %

03.08.2026

BTT

Viatris jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Marktkap.17,91 Mrd. EUR

Div. Rendite3,86%

WKNA2QAME

ISINUS92556V1061

SymbolVTRS

Viatris Aktien News

Sortieren:Datum Meistgelesen

12.05.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Viatris Inc. of Class Action Lawsuit and Upcoming Deadlines - VTRS

10.05.25PR NewswireVIATRIS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Agains...

08.05.25PR NewswireViatris Reports First Quarter 2025 Results and Reaffirms 2025 Outlook

08.05.25PR NewswireViatris Announces Positive Results from Phase 3 Study of Investigational XULANE LO™ Low Dose Patch for Birth Control in Women of Childbearing Potential

08.05.25PR NewswireViatris Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Novel Fast-Acting Meloxicam (MR-107A-02) for the Treatment of Moderate-to-Severe Acute Pain

08.05.25PR NewswireThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Viatris Inc. Lawsuit - VTRS

07.05.25PR NewswireViatris Announces Quarterly Dividend

06.05.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Viatris Inc. of Class Action Lawsuit and Upcoming Deadlines - VTRS

06.05.25PR NewswireVTRS Investors Have Opportunity to Lead Viatris Inc. Securities Fraud Lawsuit

05.05.25PR NewswireViatris Announces Appointments of Frank D'Amelio and Michael Severino, M.D., to the Company's Board of Directors

01.05.25PR NewswireJune 3, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against VTRS

28.04.25PR NewswireVTRS Investors Have Opportunity to Lead Viatris Inc. Securities Fraud Lawsuit with the Schall Law Firm

25.04.25PR NewswireViatris to Present at the BofA Securities 2025 Healthcare Conference

24.04.25PR NewswireSHAREHOLDER ALERT: Berger Montague Reminds Viatris (NASDAQ: VTRS) Investors of Class Action Lawsuit Deadline

21.04.25PR NewswireNASDAQ: VTRS INVESTOR ALERT: Berger Montague Advises Viatris (NASDAQ: VTRS) Investors of a June 3, 2025 Deadline

21.04.25PR NewswireViatris Files Supplemental New Drug Applications to Japan's Ministry of Health, Labor and Welfare for the Approval of EFFEXOR® for the Treatment of Generalized Anxiety Disorder

16.04.25PR NewswireVTRS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Viatris Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

16.04.25PR NewswireVTRS Investors Have Opportunity to Lead Viatris Inc. Securities Fraud Lawsuit

14.04.25PR NewswireViatris Appoints Hemanth J. Varghese as Chief Strategy Officer

08.04.25PR NewswireVTRS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Viatris Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

08.04.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Viatris Inc. of Class Action Lawsuit and Upcoming Deadlines - VTRS

08.04.25PR NewswireContact Levi & Korsinsky by June 3, 2025 Deadline to Join Class Action Against Viatris Inc.(VTRS)

05.04.25PR NewswireInvestor Alert: Robbins LLP Informs Stockholders of the Viatris Inc. Class Action

31.03.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viatris Inc. - VTRS

28.03.25PR NewswireViatris to Report First Quarter 2025 Financial Results on May 8, 2025

17.03.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viatris Inc. - VTRS

11.03.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viatris Inc. - VTRS

05.03.25PR NewswireViatris to Present at the Barclays 27th Annual Global Healthcare Conference

03.03.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viatris Inc. - VTRS

27.02.25PR NewswireViatris Maintains Dividend Policy for 2025 and Announces Quarterly Dividend

03.02.25PR NewswireViatris to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

07.01.25PR NewswireViatris to Present at the 43rd Annual J.P. Morgan Healthcare Conference

18.12.24PR NewswireViatris Announces Publication of Phase 2b CARE Study Data for Cenerimod in Lancet Rheumatology

05.11.24PR NewswireViatris Announces Third Quarter 2024 Dividend

29.10.24PR NewswireViatris to Participate in the UBS Global Healthcare Conference and Jefferies London Healthcare Conference

16.10.24PR NewswireViatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe

09.10.24PR NewswireViatris Announces Positive Top-line Results from Phase 3 Study of EFFEXOR® in Japanese Adults with Generalized Anxiety Disorder (GAD)

08.10.24PR NewswireViatris Named to Forbes' Annual List of the World's Best Employers for the Fourth Year in a Row

30.09.24PR NewswireViatris launches (Pr)Viagra® ODF in Canada: a new oral dissolving film form of the erectile dysfunction treatment

18.09.24PR NewswireViatris Announces the Pricing Terms of Maximum Tender Offer

Viatris News

Viatris News: auf dieser Seite finden Sie alle Viatris News und Nachrichten zur Viatris Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Viatris News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Viatris News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.